Serina Therapeutics, Inc.SEREarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
Serina Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapies for neurological and inflammatory disorders. It leverages its proprietary polyrozaxamer platform to enhance drug efficacy, safety and bioavailability, advancing lead candidates for Parkinson's disease and chronic pain for global specialty pharma markets.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Juvenescence | 79.40% | 82.7M | ▲ +0.20pp | 2023-11-16 |
| Juvenescence Limited | 42.00% | 4.5M | ▲ +4.00pp | 2024-12-09 |
| Randall | 6.80% | 615.0K | — | 2024-04-03 |
| NOS. OF ABOVE PERSONS | 2.10% | 187.5K | — | 2024-11-14 |
Insider Transactions
Net 90d: −$116.1K · buys $0 / sells $116.1KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-31 | Gregory Bailey | Director | Grant | 59.7K | $1.94 | $115.8K |
| 2026-03-31 | Jay Venkatesan | Director | Grant | 7.6K | $1.94 | $14.7K |
| 2026-03-23 | Randall Moreadith | Chief Scientific Officer | Option exercise | 6.5K | $0.06 | $390 |
| 2026-03-23 | Randall Moreadith | Chief Scientific Officer | Sell (open market) | 6.5K | $2.86 | $18.6K |
| 2026-03-19 | Randall Moreadith | Chief Scientific Officer | Option exercise | 39.0K | $0.06 | $2.3K |
| 2026-03-19 | Randall Moreadith | Chief Scientific Officer | Sell (open market) | 39.0K | $2.50 | $97.5K |
1–6 of 6